Wednesday, November 06, 2019 2:43:55 PM
(SBBP) Price:$1.70 / MCap $72 Million / Cash $79 Million / 2 Approved Drugs / Another Big Drug in Phase 3 (Cushing Syndrome) with readout in Q2 ./ Novo Nordisk owns 5.2 Million shares acquired at $7 per share ......Great buying opportunity
Largest Shareholders :
Caxton Associates LP ...6.6M
Novo Nordisk A/S ...5.2M
Longitude ...4.5M
New Enterprise ...4.1M
HealthCap AB ...3.2M
Prosight Capital ...2.5M
Broadfin ...2.5M
BlackRock ...2.1M
Armistice ...1.6M
Hudson Bay ...1.3M
Novo Nordisk to Purchase Approximately 5.2 Million Ordinary Shares of Strongbridge Biopharma plc at Purchase Price of $7.00 per Share, Resulting in Gross Proceeds of $36.7 Million ~
https://www.globenewswire.com/news-release/2018/10/31/1640246/0/en/Strongbridge-Biopharma-plc-Enters-into-Agreement-for-Novo-Nordisk-to-Acquire-the-U-S-and-Canadian-Rights-to-MACRILEN-macimorelin.html
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
